Deal Watch: Fresenius Buyout Of Akorn Potentially Threatened By Data Integrity Issues

27 Feb 2018

• By Joseph Haas, Kevin Grogan, Jung Won Shin, and Lucie Ellis-Taitt

AstraZeneca takes second license of antisense candidate under 2012 pact with Ionis, this time for kidney disease. Aldeyra is working with J&J on novel immune-modulating drugs for systemic inflammatory conditions.

Deal Watch: Fresenius Buyout Of Akorn Potentially Threatened By Data Integrity Issues

More from Deals

More from Business